Skip to main content

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Veeva Systems (VEEV)

Tipranks - Tipranks - Wed Mar 11, 1:22PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tyra Bioscience (TYRA – Research Report) and Veeva Systems (VEEV – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Tyra Bioscience (TYRA)

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Tyra Bioscience. The company’s shares closed last Tuesday at $34.40.

According to TipRanks.com, Buren is a 5-star analyst with an average return of 22.0% and a 55.2% success rate. Buren covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Crinetics Pharmaceuticals, and Maze Therapeutics, Inc. ;'>

Currently, the analyst consensus on Tyra Bioscience is a Strong Buy with an average price target of $48.71, which is a 44.8% upside from current levels. In a report issued on February 24, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock.

See the top stocks recommended by analysts >>

Veeva Systems (VEEV)

William Blair analyst Dylan Becker maintained a Buy rating on Veeva Systems today. The company’s shares closed last Tuesday at $189.11.

According to TipRanks.com, Becker is a 3-star analyst with an average return of 1.0% and a 42.1% success rate. Becker covers the Technology sector, focusing on stocks such as CCC Intelligent Solutions Holdings, Clearwater Analytics Holdings, and Manhattan Associates. ;'>

Currently, the analyst consensus on Veeva Systems is a Moderate Buy with an average price target of $266.36, which is a 36.3% upside from current levels. In a report issued on February 23, TipRanks – xAI also upgraded the stock to Buy with a $199.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).